VJHemOnc is committed to improving our service to you

ASH 2018 | Rivaroxaban for thromboprophylaxis in high-risk cancer patients: CASSINI results

VJHemOnc is committed to improving our service to you

Alok Khorana

The CASSINI trial investigated the use of rivaroxaban to prevent the development of blood clots in high-risk ambulatory cancer patients receiving systemic therapy. Alok Khorana, MD, of the Cleveland Clinic, Cleveland, OH, presents the data at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter